Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Upfront modified FOLFOXIRI plus panitumumab improves OS in RAS/BRAF wild-type mCRC

Dr Veronica Conca - University of Pisa, Pisa, Italy
Upfront modified FOLFOXIRI plus panitumumab improves OS in RAS/BRAF wild-type mCRC ( Dr Veronica Conca - University of Pisa, Pisa, Italy )
2 Jun 2025

Primary cytoreductive surgery shows PFS benefit in advanced ovarian cancer

Prof Sven Mahner - Ludwig Maximilian University of Munich, Munich, Germany
Primary cytoreductive surgery shows PFS benefit in advanced ovarian cancer ( Prof Sven Mahner - Ludwig Maximilian University of Munich, Munich, Germany )
2 Jun 2025

New MOAs in prostate cancer treatment - what’s next?

Dr Joaquin Mateo, Dr Andrew Parsonson and Dr Capucine Baldini
New MOAs in prostate cancer treatment - what’s next? ( Dr Joaquin Mateo, Dr Andrew Parsonson and Dr Capucine Baldini )
2 Jun 2025

Molecular assay may help identify NSCLC patients who could benefit from adjuvant chemotherapy

Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA
Molecular assay may help identify NSCLC patients who could benefit from adjuvant chemotherapy ( Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA )
2 Jun 2025

Trastuzumab deruxtecan plus pertuzumab may delay cancer growth for some HER2-positive advanced breast cancers

Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA
Trastuzumab deruxtecan plus pertuzumab may delay cancer growth for some HER2-positive advanced breast cancers ( Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA )
2 Jun 2025

Neoadjuvant gemcitabine and cisplatin improves OS in resectable biliary tract cancer

Dr Thorsten Oliver Goetze - The University Cancer Center (UCT), Frankfurt, Germany
Neoadjuvant gemcitabine and cisplatin improves OS in resectable biliary tract cancer ( Dr Thorsten Oliver Goetze - The University Cancer Center (UCT), Frankfurt, Germany )
1 Jun 2025

Trastuzumab deruxtecan benefit for some advanced gastric cancers

Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan
Trastuzumab deruxtecan benefit for some advanced gastric cancers ( Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan )
1 Jun 2025

HER2-positive breast cancer: Predicting pCR from clinicopathologic variables and genomic testing

Dr Nadine M Tung - Beth Israel Deaconess Medical Center, Boston, USA
HER2-positive breast cancer: Predicting pCR from clinicopathologic variables and genomic testing ( Dr Nadine M Tung - Beth Israel Deaconess Medical Center, Boston, USA )
1 Jun 2025

Tumor Treating Fields plus chemo shows OS benefit in unresectable pancreatic cancer

Dr Vincent Picozzi - Virginia Mason Medical Center, Seattle, USA
Tumor Treating Fields plus chemo shows OS benefit in unresectable pancreatic cancer ( Dr Vincent Picozzi - Virginia Mason Medical Center, Seattle, USA )
1 Jun 2025

ASCO 2025: Latest in EGFR positive NSCLC

Prof Pascale Tomasini, Prof Enriqueta Felip, Prof Nicolas Girard
ASCO 2025: Latest in EGFR positive NSCLC ( Prof Pascale Tomasini, Prof Enriqueta Felip, Prof Nicolas Girard )
1 Jun 2025

Perioperative durvalumab and FLOT chemo can reduce risk of recurrence for some gastric cancers

Dr Yelena Janjigian - Memorial Sloan Kettering Cancer Center, New York, USA
Perioperative durvalumab and FLOT chemo can reduce risk of recurrence for some gastric cancers ( Dr Yelena Janjigian - Memorial Sloan Kettering Cancer Center, New York, USA )
1 Jun 2025

BCG combined with mitomycin offers improved adjuvant treatment regimen for high-risk NMIBC

Prof Dickon Hayne - University of Western Australia, Perth, Australia
BCG combined with mitomycin offers improved adjuvant treatment regimen for high-risk NMIBC ( Prof Dickon Hayne - University of Western Australia, Perth, Australia )
1 Jun 2025